FibroBiologics (FBLG)
Nasdaq Market Closed
FibroBiologics, Inc. is a clinical-stage biotechnology company developing cell-based therapies built around fibroblasts, a type of cell best known for its role in connective tissue formation, wound repair, and extracellular matrix production. The company’s work sits within regenerative medicine, where researchers aim to use living cells or cell-derived biology to repair damaged tissue, modulate immune activity, and address diseases that have limited treatment options.
FibroBiologics is focused on chronic and degenerative conditions with significant unmet medical need. Its pipeline includes product candidates directed at wound healing, multiple sclerosis, degenerative disc disease, psoriasis, and oncology-related applications. The company also explores potential longevity-related uses, including approaches connected to thymic involution, the age-related shrinking of the thymus that affects immune function. Its named candidates include CYWC628, CYPS317, CYMS101, and CybroCell.
As a biotechnology stock, FibroBiologics is defined less by current commercial sales than by the progress, safety, and clinical potential of its research programs. The company must advance candidates through preclinical work, clinical trials, manufacturing development, and regulatory review before any therapy can become widely available. That makes the business highly research-driven and dependent on capital access, scientific execution, and regulatory milestones.
For investors following FBLG, the key point of differentiation is its fibroblast-centered platform. Rather than focusing on a single small-molecule drug or antibody, FibroBiologics is attempting to build a broader therapeutic approach around a cell type involved in tissue remodeling and immune signaling.
Last updated
- Market Cap
- 5.47M
- P/E
- —
- P/FCF
- —
- P/S
- —
- Enterprise Value
- 4.23M
- Sector
- Health Care
- Industry
- Pharmaceutical Preparations
- Address
- 455 E. MEDICAL CENTER BLVD, HOUSTON, TX, 77598
FibroBiologics Reports Q1 2026 Financial Results and Provides Corporate Update
The Psoriasis Clinical Trial Pipeline Boom as 90+ Companies are in the Race for Better Treatments | DelveInsight
FibroBiologics Announces Pricing of $3 Million Public Offering
FibroBiologics Announces Closing of $4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
FibroBiologics annonce des progrès scientifiques suite à la confirmation des résultats relatifs à la réparation de tissus cérébraux
FibroBiologics gibt wissenschaftlicher Fortschritte bei der Reparatur von Hirngewebe bekannt
FibroBiologics dépose une demande de brevet pour une nouvelle approche visant à moduler l’activité mitochondriale à l’aide de produits thérapeutiques à base de fibroblastes
FibroBiologics meldet Patent für neuartigen Ansatz zur Modulation mitochondrialer Aktivität mithilfe von auf Fibroblasten basierten Therapeutika an
D. Boral Capital Served as Exclusive Placement Agent to FibroBiologics, Inc. (Nasdaq: FBLG) in connection with its $25.0 Million Financing
FibroBiologics Announces $25 Million Financing
FibroBiologics Files 2024 Second Quarter Report
FibroBiologics Announces Preliminary Proof of Concept for Novel Artificial Thymus Organoid Technology
FibroBiologics Set to Join Russell 2000® Index
FibroBiologics to Present at Extracellular Matrix Pharmacology Congress 2024
FibroBiologics Announces 2024 Annual Meeting of Stockholders
FibroBiologics Files 2024 First Quarter Report
FibroBiologics to Present at the BIO International Convention 2024
FibroBiologics Granted Patent for Regeneration of Cartilage-Type Cells by the Australian Patent Office
FibroBiologics Presents Data from Dermal Fibroblast Spheroid-based Treatment of Chronic Wounds in a Diabetes Mouse Model at Advanced Wound Care Summit USA
FibroBiologics Files Patent Application Covering Fibroblast-based Technology for the Potential Treatment of Lupus
- Market Cap
Market cap is the total value of a company's shares, calculated by multiplying the stock price by the number of shares outstanding.
- 5.47M
- Enterprise Value
Enterprise value is the total value of a company, including its market cap, debt, and cash.
- 4.23M
- P/E
P/E ratio compares a company's share price to its earnings per share.
- —
- P/B
P/B ratio compares a company's share price to its book value per share.
- 2.1
- P/S
P/S ratio compares a company's share price to its revenue per share.
- —
- EV / EBITDA
EV/EBITDA measures a company's value compared to its earnings before interest, taxes, depreciation, and amortization.
- -0.26
- EV / Sales
EV/Sales measures a company's value compared to its total revenue.
- —
- EPS
- -3.59
- Dividend Yield
Dividend yield shows how much a company pays in dividends each year compared to its share price.
- 0%
- P/FCF
Price-to-free-cash-flow ratio compares a company's share price to the cash it generates after expenses and investments.
- —
- P/CF
P/CF ratio compares a company's share price to the cash flow it generates from its operations.
- —
- Free Cash Flow
Free cash flow is the cash a company has left after covering operating costs and capital expenses.
- -15.7M
- ROE
ROE measures how effectively a company uses shareholders' equity to generate profit.
- -718.46%
- ROA
ROA measures how effectively a company uses its assets to generate profit.
- -314.58%
- Debt / Equity
Debt-to-equity ratio compares a company's total debt to its shareholders' equity.
- 0.09
- Current Ratio
Current ratio measures a company's ability to pay short-term debts using its short-term assets.
- 1.59
- Quick Ratio
Quick ratio measures a company's ability to pay short-term debts using cash and other easily available assets.
- 1.59
- Cash
Cash ratio measures a company's ability to cover short-term debts using only cash and cash equivalents.
- 0.81
- Avg Volume
Average volume shows the average number of shares traded over the last 30 trading days, helping indicate liquidity.
- 279.5K
- Fundamentals Snapshot Price
Fundamentals snapshot price is the stock price used when calculating the company's financial ratios and metrics.
- 1.05
Income Statement
| Line Item | 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | 2025 Q1 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -5.07M | -2.59M | -5.04M | -4.49M | -4.53M |
| EBITDA | -5M | -1.94M | -4.97M | -4.43M | -4.48M |
| Net income | -5M | -3.24M | -5.78M | -4.66M | -4.97M |
| Basic EPS | -1.33 | -0.6 | -2.6 | -2.4 | -2.71 |
| Diluted EPS | -1.33 | -0.6 | -2.6 | -2.4 | -2.71 |
Balance Sheet
| Line Item | 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | 2025 Q1 |
|---|---|---|---|---|---|
| Total assets | 5.94M | 9.62M | 8.74M | 13.91M | 11.43M |
| Total liabilities | 3.34M | 3.46M | 8.62M | 13.05M | 9.08M |
| Total equity | 2.6M | 6.16M | 125K | 860K | 2.35M |
| Cash & equivalents | 1.48M | 4.89M | 4.87M | 8.85M | 8.67M |
| Current assets | 2.91M | 6.35M | 5.24M | 10.18M | 9.33M |
| Current liabilities | 1.83M | 1.76M | 6.72M | 10.96M | 8.21M |
Cash Flow
| Line Item | 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | 2025 Q1 |
|---|---|---|---|---|---|
| Operating cash flow | -4.36M | -3.16M | -3.97M | -3.98M | -5.28M |
| Investing cash flow | — | 0 | -6K | -213K | -43K |
| Financing cash flow | 952K | 3.19M | 0 | 4.38M | — |
| Change in cash | -3.41M | 27K | -3.98M | 178K | -5.32M |
| Kind | Filing | Date | Link |
|---|---|---|---|
| edgar index | 424B5 — FibroBiologics, Inc. | View Filing | |
| edgar index | 8-K — FibroBiologics, Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | DEF 14A — FibroBiologics, Inc. | View Filing | |
| edgar index | DEFA14A — FibroBiologics, Inc. | View Filing | |
| edgar index | ARS — FibroBiologics, Inc. | View Filing | |
| edgar index | 8-K — FibroBiologics, Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 4 — FibroBiologics, Inc. | View Filing | |
| edgar index | 4 — FibroBiologics, Inc. | View Filing | |
| edgar index | 4 — FibroBiologics, Inc. | View Filing | |
| edgar index | 4 — FibroBiologics, Inc. | View Filing | |
| form 4 | Form 4 — GARCIA RUBEN A | View Filing | |
| form 4 | Form 4 — Davis Jason | View Filing | |
| form 4 | Form 4 — Khoja Hamid | View Filing | |
| form 4 | Form 4 — O'HEERON PETE | View Filing | |
| edgar index | 8-K — FibroBiologics, Inc. | View Filing | |
| edgar index | 424B5 — FibroBiologics, Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | PRE 14A — FibroBiologics, Inc. | View Filing | |
| edgar index | 8-K — FibroBiologics, Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 8-K — FibroBiologics, Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | SCHEDULE 13G — FibroBiologics, Inc. | View Filing | |
| edgar index | 8-K — FibroBiologics, Inc. | View Filing | |
| edgar index | 8-K/A — FibroBiologics, Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 8-K — FibroBiologics, Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 8-K — FibroBiologics, Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 424B4 — FibroBiologics, Inc. | View Filing | |
| edgar index | EFFECT — FibroBiologics, Inc. | View Filing | |
| edgar index | S-1 — FibroBiologics, Inc. | View Filing | |
| edgar index | CORRESP — FibroBiologics, Inc. | View Filing | |
| edgar index | CORRESP — FibroBiologics, Inc. | View Filing | |
| edgar index | UPLOAD — FibroBiologics, Inc. | View Filing | |
| edgar index | DRS — FibroBiologics, Inc. | View Filing | |
| edgar index | 10-K/A — FibroBiologics, Inc. | View Filing | |
| edgar index | 8-K — FibroBiologics, Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 4 — FibroBiologics, Inc. | View Filing | |
| edgar index | 4 — FibroBiologics, Inc. | View Filing | |
| form 4 | Form 4 — O'HEERON PETE | View Filing | |
| form 4 | Form 4 — Khoja Hamid | View Filing | |
| edgar index | 4 — FibroBiologics, Inc. | View Filing | |
| form 4 | Form 4 — O'HEERON PETE | View Filing | |
| edgar index | 4 — FibroBiologics, Inc. | View Filing | |
| form 4 | Form 4 — Davis Jason | View Filing | |
| form 4 | Form 4 — O'HEERON PETE | View Filing | |
| form 4 | Form 4 — GARCIA RUBEN A | View Filing | |
| edgar index | 10-K — FibroBiologics, Inc. | View Filing | |
| ten k section | 10-K — business | View Filing | |
| ten k section | 10-K — mda | View Filing | |
| ten k section | 10-K — risk_factors | View Filing | |
| edgar index | 8-K — FibroBiologics, Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 8-K — FibroBiologics, Inc. | View Filing | |
| edgar index | 8-K — FibroBiologics, Inc. | View Filing | |
| edgar index | 424B3 — FibroBiologics, Inc. | View Filing | |
| edgar index | EFFECT — FibroBiologics, Inc. | View Filing | |
| edgar index | DEF 14A — FibroBiologics, Inc. | View Filing | |
| edgar index | DEFA14A — FibroBiologics, Inc. | View Filing | |
| edgar index | S-1 — FibroBiologics, Inc. | View Filing | |
| edgar index | DEF 14A — FibroBiologics, Inc. | View Filing | |
| edgar index | PRE 14A — FibroBiologics, Inc. | View Filing | |
| edgar index | D — FibroBiologics, Inc. | View Filing | |
| edgar index | 424B5 — FibroBiologics, Inc. | View Filing | |
| edgar index | 8-K — FibroBiologics, Inc. | View Filing | |
| edgar index | 4 — FibroBiologics, Inc. | View Filing | |
| form 4 | Form 4 — GARCIA RUBEN A | View Filing | |
| edgar index | D — FibroBiologics, Inc. | View Filing | |
| edgar index | D — FibroBiologics, Inc. | View Filing | |
| edgar index | 424B5 — FibroBiologics, Inc. | View Filing |